Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRINASDAQ:HEPANASDAQ:ONVONASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.82+9.0%$4.54$1.10▼$106.04$877K-1.72281,127 shs241,291 shsHEPAHepion Pharmaceuticals$0.29-0.9%$2.34$0.25▼$79.50$3.16M1.791.04 million shs540,538 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsSPRCSciSparc$0.29-2.0%$0.33$0.20▼$1.79$3.10M0.653.69 million shs542,480 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio-9.24%+10.60%-75.07%-84.02%-98.27%HEPAHepion Pharmaceuticals+2.11%-9.97%-59.33%-96.96%-99.56%ONVOOrganovo0.00%+18.60%-28.17%-50.29%-83.00%SPRCSciSparc+1.71%+3.29%-11.01%-49.43%-75.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRIGRI Bio2.3453 of 5 stars3.52.00.00.03.30.01.3HEPAHepion Pharmaceuticals0.1109 of 5 stars0.02.00.00.00.60.00.6ONVOOrganovo0.5206 of 5 stars0.03.00.00.02.40.00.6SPRCSciSparc0.3597 of 5 stars0.04.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 3.00Buy$115.506,246.15% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/AONVOOrganovo 0.00N/AN/AN/ASPRCSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRI, ONVO, HEPA, and SPRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$5.22 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/AONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00SPRCSciSparc$1.75M1.77N/AN/A$13.57 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%5/9/2025 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%5/20/2025 (Estimated)ONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%5/30/2025 (Estimated)SPRCSciSparc-$5.12MN/A0.00∞N/AN/AN/AN/AN/ALatest GRI, ONVO, HEPA, and SPRC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025N/AGRIGRI Bio-$4.08N/AN/AN/AN/AN/A2/19/2025Q3 2025ONVOOrganovo-$2.52-$2.28+$0.24-$0.19$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI Bio$1.91104.95%N/AN/A N/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A3.103.10HEPAHepion PharmaceuticalsN/A1.301.30ONVOOrganovoN/A0.721.72SPRCSciSparcN/A1.861.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%HEPAHepion Pharmaceuticals17.24%ONVOOrganovo8.23%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio0.13%HEPAHepion Pharmaceuticals4.70%ONVOOrganovo3.72%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio1525,0008.92 millionNot OptionableHEPAHepion Pharmaceuticals2010.98 million6.63 millionNo DataONVOOrganovo201.70 million14.79 millionOptionableSPRCSciSparc410.83 million10.20 millionNot OptionableGRI, ONVO, HEPA, and SPRC HeadlinesRecent News About These CompaniesScisparc and Clearmind Push into Eating Disorder And Addiction Treatment With New PatentsApril 25 at 10:57 AM | theglobeandmail.comSciSparc and Clearmind File Patent for Eating Disorder TreatmentApril 25 at 8:55 AM | tipranks.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersApril 25 at 7:59 AM | globenewswire.comSciSparc Extends Deadline for Miza III Ventures DealApril 1, 2025 | tipranks.comSciSparc Ltd. Extends Merger Agreement with AutoMax MotorsApril 1, 2025 | tipranks.comSciSparc files to sell 61.21M ordinary shares for holdersMarch 26, 2025 | markets.businessinsider.comSciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent ApplicationMarch 11, 2025 | tipranks.comClearmind Medicine Inc.: Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South KoreaMarch 10, 2025 | finanznachrichten.deSciSparc announces publication of patent via Clearmind collaborationMarch 10, 2025 | markets.businessinsider.comSciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine AddictionMarch 10, 2025 | quiverquant.comSciSparc Ltd. Agrees to Sell MitoCareX to N2OFFMarch 3, 2025 | tipranks.comSciSparc Ltd: SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant CancersMarch 3, 2025 | finanznachrichten.deSciSparc signs definitive agreement to sell MitoCareX to N2OFFMarch 3, 2025 | markets.businessinsider.comSciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange AgreementMarch 3, 2025 | quiverquant.comSciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant CancersMarch 3, 2025 | globenewswire.comSciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric VehiclesFebruary 27, 2025 | markets.businessinsider.comSciSparc Enters $4.2M Securities Agreement and Supports AutoMax Expansion with $2M LoanFebruary 27, 2025 | tipranks.comSciSparc Ltd. Enters $2 Million Loan Agreement with AutoMax Motors to Support Business ExpansionFebruary 27, 2025 | quiverquant.comSciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric VehiclesFebruary 27, 2025 | globenewswire.comN2OFF signs definitive agreement to acquire MitoCareX from SciSparcFebruary 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialWhy Analysts See Double-Digit Upside in CAVA StockBy Gabriel Osorio-Mazilli | April 6, 2025View Why Analysts See Double-Digit Upside in CAVA StockAmazon's Earnings Could Fuel a Rapid Breakout By Sam Quirke | April 23, 2025View Amazon's Earnings Could Fuel a Rapid Breakout GRI, ONVO, HEPA, and SPRC Company DescriptionsGRI Bio NASDAQ:GRI$1.82 +0.15 (+8.98%) As of 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Hepion Pharmaceuticals NASDAQ:HEPA$0.29 0.00 (-0.86%) Closing price 04:00 PM EasternExtended Trading$0.28 0.00 (-1.22%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.SciSparc NASDAQ:SPRC$0.29 -0.01 (-2.02%) Closing price 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.70%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
